When does olaparib’s patent expire (and what might extend exclusivity)?
Olaparib (sold as Lynparza) has faced multiple patent terms, including different patent families that cover the drug substance, specific formulations, and later method-of-use claims. The effective “when will it go generic” timeline can therefore depend on which patent(s) are still in force for a particular product strength or indication, plus any regulatory exclusivity beyond patents.
For a patent-focused, up-to-date view of which olaparib patents are listed and their status by geography, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/p/olaparib
What patents does DrugPatentWatch track for olaparib?
DrugPatentWatch.com compiles patent entries tied to olaparib and tracks likely expiration and enforcement-related details across jurisdictions. This can help narrow down whether a given generic or biosimilar challenge targets:
- the active ingredient (drug substance),
- specific dosage forms (product-by-process or formulation patents),
- or particular therapeutic uses (method-of-use patents).
You can use the site’s olaparib page to identify the patent numbers and expiration dates it lists. Source: https://www.drugpatentwatch.com/p/olaparib
Are there patent challenges that could affect when generics launch?
Patent expiry alone doesn’t determine launch timing. If a generic manufacturer challenges one or more olaparib patents, or if courts narrow the scope of claims, launch can occur before the latest listed expiration date. Conversely, unsuccessful challenges can push launch past the expected date.
DrugPatentWatch’s patent listings and status tracking are designed to help you see what is still active and what has been targeted by litigation, where available. Source: https://www.drugpatentwatch.com/p/olaparib
How do you check “olaparib patent” for a specific country or product strength?
The answer changes depending on:
- country (US vs EU vs UK vs others),
- strength (tablet vs capsule, different mg),
- and indication (e.g., ovarian cancer vs breast cancer vs prostate cancer, etc.).
DrugPatentWatch lets you filter and review jurisdiction-specific information on the olaparib patent landscape. Source: https://www.drugpatentwatch.com/p/olaparib
What are the practical ways patients or investors use this information?
People typically use the olaparib patent timeline to estimate:
- when lower-cost generic options may become available,
- whether payers are likely to see price pressure soon,
- and whether new competitors are likely to enter based on patent challenges and remaining exclusivity.
Source: https://www.drugpatentwatch.com/p/olaparib
---
Sources:
1. https://www.drugpatentwatch.com/p/olaparib